NK cytolysis is dependent on the proportion of HLA-G expression

Human Immunology

Volumn 74, Issue 3, 2013, Pages 286-289

  Chen, Bao Guo ^a   Xu, Dan Ping ^a   Lin, Aifen ^a   Yan, Wei Hua ^a,b  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; HLA G ANTIGEN; HLA G1 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL STRAIN K 562; CELL SURFACE; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HLA-G ANTIGENS; HUMANS; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, ERYTHROBLASTIC, ACUTE; TRANSFECTION;

EID: 84873744799     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.12.005     Document Type: Article

References (39)

1. Yan W.H., Lin A. HLA-G: biology, functions and roles in disease. Major Histocompatibility Complex: Biology, Functions and Roles in Disease 2012, 79-117. Nova Science Publishers, Inc., New York. N.V. Semiletova (Ed.).
2. Yan W.H. Human leukocyte antigen-G in cancer: are they clinically relevant?. Cancer Lett 2011, 311:123-130.
3. Baudhuin J., Lesport E., Sousa S., Migraine J., Vigneron J., Lemaoult J., et al. HLA-G inhibition of NK-cell cytolytic function is uncoupled from tumor cell lipid raft reorganization. Eur J Immunol 2012, 42:700-709.
4. Zhong M., Weng X., Liang Z., Lu S., Li J., Chen X., et al. Dimerization of soluble HLA-G by IgG-Fc fragment augments ILT2-mediated inhibition of T-cell alloresponse. Transplantation 2009, 87:8-15.
5. Gregori S., Tomasoni D., Pacciani V., Scirpoli M., Battaglia M., Magnani C.F., et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010, 116:935-944.
6. Zeng M.H., Fang C.Y., Wang S.S., Zhu M., Xie L., Li R., et al. A study of soluble HLA-G1 protecting porcine endothelial cells against human natural killer cell-mediated cytotoxicity. Transplant Proc 2006, 38:3312-3314.
7. Gregori S., Magnani C.F., Roncarolo M.G. Role of human leukocyte antigen-G in the induction of adaptive type 1 regulatory T cells. Hum Immunol 2009, 70:966-969.
8. Giuliani M., Giron-Michel J., Negrini S., Vacca P., Durali D., Caignard A., et al. Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS One 2008, 3:e2241.
9. Bahri R., Naji A., Menier C., Charpentier B., Carosella E.D., Rouas-Freiss N., et al. Dendritic cells secrete the immunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplant acceptance. J Immunol 2009, 183:7054-7062.
10. Caumartin J., Favier B., Daouya M., Guillard C., Moreau P., Carosella E.D., et al. Trogocytosis-based generation of suppressive NK cells. EMBO J 2007, 26:1423-1433.
11. LeMaoult J., Caumartin J., Daouya M., Favier B., Le Rond S., Gonzalez A., et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007, 109:2040-2048.
12. Carosella E.D., Moreau P., Le Maoult J., Le Discorde M., Dausset J., Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003, 81:199-252.
13. Murdaca G., Contini P., Setti M., Cagnati P., Lantieri F., Indiveri F., et al. Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. Clin Immunol 2009, 133:238-244.
14. Murdaca G., Contini P., Setti M., Cagnati P., Spanò F., Lantieri F., et al. Soluble human leukocyte antigen-G serum levels in patients with acquired immune deficiency syndrome affected by different disease-defining conditions before and after antiretroviral treatment. Hum Immunol 2011, 72:712-716.
15. Paul P., Rouas-Freiss N., Khalil-Daher I., Moreau P., Riteau B., Le Gal F.A., et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998, 95:4510-4515.
16. Yan W.H. HLA-G expression in hematologic malignancies. Expert Rev Hematol 2010, 3:67-80.
17. Yan W.H. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets 2011, 11:76-89.
18. Agaugué S., Carosella E.D., Rouas-Freiss N. Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17. Blood 2011, 117:7021-7031.
19. Lesport E., Baudhuin J., Sousa S., LeMaoult J., Zamborlini A., Rouas-Freiss N., et al. Inhibition of human gamma delta T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci 2011, 68:3385-3399.
20. Lin A., Zhang X., Xu H.H., Xu D.P., Ruan Y.Y., Yan W.H. HLA-G expression is associated with metastasis and poor survival in the Balb/c nu/nu murine tumor model with ovarian cancer. Int J Cancer 2012, 131:150-157.
21. Brown R., Kabani K., Favaloro J., Yang S., Ho P.J., Gibson J., et al. CD86+ or HLA-G+ myeloma cells are associated with poor prognosis and once acquired by trogocytosis create novel Tregacq cells. Blood 2012, 120:2055-2063.
22. Goldman-Wohl D., Ariel I., Greenfield C., Hochner-Celnikier D., Lavy Y., Yagel S. A study of human leukocyte antigen G expression in hydatidiform moles. Am J Obstet Gynecol 2001, 185:476-480.
23. Hurks H.M., Valter M.M., Wilson L., Hilgert I., van den Elsen P.J., Jager M.J. Uveal melanoma: no expression of HLA-G. Invest Ophthalmol Vis Sci 2001, 42:3081-3084.
24. Lin A., Yan W.H., Xu H.H., Gan M.F., Cai J.F., Zhu M., et al. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol 2007, 18:1804-1809.
25. Alter G., Malenfant J.M., Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004, 294:15-22.
26. Aktas E., Kucuksezer U.C., Bilgic S., Erten G., Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009, 254:149-154.
27. Thielens A., Vivier E., Romagné F. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 2012, 24:239-245.
28. Campoli M., Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 2011, 33:321-334.
29. Gomes A.Q., Correia D.V., Silva-Santos B. Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance. EMBO Rep 2007, 8:1024-1030.
30. Carosella E.D., Gregori S., Rouas-Freiss N., LeMaoult J., Menier C., Favier B. The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci 2011, 68:353-368.
31. Amiot L., Ferrone S., Grosse-Wilde H., Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?. Cell Mol Life Sci 2011, 68:417-431.
32. Pistoia V., Morandi F., Wang X., Ferrone S. Soluble HLA-G: are they clinically relevant?. Semin Cancer Biol 2007, 17:469-479.
33. Seliger B., Abken H., Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003, 24:82-87.
34. Yan W.H., Lin A., Chen B.G., Luo W.D., Dai M.Z., Chen X.J., et al. Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia. J Cell Mol Med 2008, 12:889-898.
35. Lin A., Zhu C.C., Chen H.X., Chen B.F., Zhang X., Zhang J.G., et al. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer. J Cell Mol Med 2010, 14:2318-2329.
36. Bukur J., Rebmann V., Grosse-Wilde H., Luboldt H., Ruebben H., Drexler I., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003, 63:4107-4111.
37. Kapasi K., Albert S.E., Yie S., Zavazava N., Librach C.L. HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 2000, 101:191-200.
38. Wiendl H., Mitsdoerffer M., Hofmeister V., Wischhusen J., Bornemann A., Meyermann R., et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002, 168:4772-4780.
39. Rouas-Freiss N., Moreau P., Ferrone S., Carosella E.D. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 2005, 65:10139-10144.